More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$826800368
EPS
0.8
P/E ratio
15
Price to sales
2.58
Dividend yield
--
Beta
1.095874
Previous close
$8.74
Today's open
$8.70
Day's range
$8.25 - $8.70
52 week range
$6.62 - $15.35
show more
CEO
Alexandria Forbes
Employees
393
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
97730540
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MeiraGTx Announces Oral Presentation at ObesityWeek 2026
Presentation highlights the Company's AAV-BDNF program for the treatment of severe early-onset obesity Presentation highlights the Company's AAV-BDNF program for the treatment of severe early-onset obesity
GlobeNewsWire • Nov 16, 2026

MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026 Submission of full Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bota-vec expected in the first quarter of 2027 12-month data readout in pivotal Phase 2 AQUAx2 study of AAV2-hAQP1 for the treatment of radiation-induced xerostomia (RIX) mid-2027 Upcoming oral presentation at ObesityWeek highlights AAV-BDNF program for the treatment of MC4R/BDNF genetic obesity (severe early-onset syndromic obesity) Strengthened leadership with the appointment of John Knighton as Executive Vice President of Global Manufacturing and Supply Chain and Alan M. Sebulsky to the Board of Directors LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2026, and provided a corporate update.
GlobeNewsWire • Nov 12, 2026

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.62 per share a year ago.
Zacks Investment Research • Nov 12, 2026

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms
GlobeNewsWire • Oct 27, 2026

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
GlobeNewsWire • Sep 23, 2026

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy. GV101's 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
PRNewsWire • Aug 26, 2026

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027 LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update. “During the second quarter of 2026, we made tremendous progress towards transforming MeiraGTx into a commercial company,” said Alexandria Forbes, Ph.D.
GlobeNewsWire • Aug 13, 2026

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.
Zacks Investment Research • Aug 13, 2026

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).
PRNewsWire • Aug 11, 2026

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards under the Company's 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MeiraGTx Holdings plc commission-free¹. Build wealth for the long term using automated trading and transfers.